09.02.2017
Evotec AG DE0005664809
DGAP-News: Novo A/S becomes new long-term strategic shareholder in Evotec
DGAP-News: Evotec AG / Key word(s): Capital Increase
Novo A/S becomes new long-term strategic shareholder in Evotec
09.02.2017 / 21:34
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Novo A/S invests EUR 90.3 m in new Evotec shares resulting in ownership
of approx. 8.9% after the capital increase
- New long-term shareholding to strengthen Evotec's strategic business case
in the drug discovery outsourcing industry
Hamburg, Germany, 09 February 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced that it resolved on a capital increase from its authorised
capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S
(Denmark).
In this private placement capital increase, Novo A/S will invest EUR 90.3 m
to subscribe shares of Evotec at a price of EUR 6.87 per share. The
placement was made at a zero discount to the XETRA closing auction price of
the Evotec stock on 09 February 2017. With the registration of the capital
increase in the commercial register, the share capital of the Company will
increase to EUR 146,197,758.00 or 146,197,758 ordinary bearer shares
respectively.
Evotec continues to pursue a very focused innovation and roll-up strategy
in the outsourcing and external innovation drug discovery industry. Evotec
has expanded its operations internationally with more than 1,200 scientists
at year-end 2016 in Germany, France, UK and the USA and with more than EUR
150 m (e) revenues. Evotec has become a recognised leader in this industry.
In the long term, Evotec aims to become the globally leading science-driven
drug discovery company, creating a network of high-value partnerships and a
co-owned drug development pipeline with its partners. This investment from
Novo A/S will be used to support and accelerate this underlying business
case.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are
delighted that Novo A/S, a highly regarded and well-known long-term
investor has made this investment in Evotec. This investment will allow us
to accelerate our strategy to expand and invest in our best-in-class
platform and outsourcing services and to build and invest in promising Cure
X and Target X initiatives together with top academic partners and biotech
globally."
Michael Shalmi, Managing Director of Large Investment at Novo A/S, added:
"Novo A/S is very excited about the prospects for our investment in Evotec
based on the company's development and the growth dynamics of the global
market for external innovation and outsourcing within drug discovery. This
investment in Evotec underscores our interest in supporting companies that
make a real difference in the healthcare industry and provide more
efficient solutions for the rapidly changing value chain in drug discovery
and development. The investment fits our long-term investment strategy very
well."
ABOUT NOVO A/S
Novo A/S is a private limited liability company wholly owned by the Novo
Nordisk Foundation. Novo A/S is the holding company in the Novo Group and
responsible for managing the Foundation's assets. Besides being the major
shareholder in the Novo Group companies, Novo A/S provides seed and venture
capital to development-stage companies, takes significant ownership
positions in well-established companies within the life sciences and
manages a broad portfolio of financial assets. Read more at www.novo.dk.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes with Pfizer in
the field of tissue fibrosis and with Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
09.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
543555 09.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT